Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 0.65 |
| ▸ | CNR2 | P34972 | 2/20 | 0.65 |
| ▸ | EIF4E | P06730 | 1/20 | 0.47 |
| ▸ | CDC7 | O00311 | 2/20 | 0.47 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | MARS1 | P56192 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1250874 | 0.93 | CNR1 (0.57) | CNR1CNR2EIF4ECDC7DBF4 | |
| SCHEMBL5034224 | 0.92 | CNR1 (0.57) | CNR1CNR2EIF4ECDC7DBF4 | |
| SCHEMBL5043907 | 0.89 | CNR1 (0.65) | CNR1CNR2EIF4ECDC7DBF4 | |
| SCHEMBL5038585 | 0.88 | CNR1 (0.64) | CNR1CNR2CDC7DBF4CCNE1 | |
| SCHEMBL5036951 | 0.84 | CNR1 (0.67) | CNR1CNR2KDM4ENPC1RAB9A | |
| SCHEMBL5909542 | 0.84 | KDM4E (0.49) | CNR1CNR2KDM4ENPC1RAB9A | |
| SCHEMBL6190763 | 0.82 | CNR1 (0.85) | CNR1CNR2 | |
| SCHEMBL5034238 | 0.82 | CDC7 (0.60) | CNR1CNR2CDC7DBF4KDM4E | |
| SCHEMBL5038528 | 0.81 | CNR1 (0.61) | CNR1CNR2 | |
| SCHEMBL5038462 | 0.80 | CNR1 (0.60) | CNR1CNR2CDC7DBF4CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122229-A1 | 4,5-diarylthiazole derivatives as cb-1 ligands | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | claimed |
| EP-2026798-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CBX CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS | Solvay Pharmaceuticals GmbH (DE) | 2009-02-25 | — | — | EP | disclosed |
| US-7342032-B2 | Thiazole derivatives having CB1-antagonistic, agonistic or partial agonistic activity | SOLVAY PHARMACEUTICALS, INC. (NL) | 2008-03-11 | — | — | US | disclosed |
| WO-2007125048-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CBX CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-08 | — | — | WO | disclosed |
| US-20060141043-A1 | Aqueous dispersion comprising stable nanoparticles of a water-insoluble thiazole derivative and excipients like middle chain triglycerides | ASTRAZENECA A B (SE) | 2006-06-29 | — | — | US | disclosed |
| US-20060122229-A1 | 4,5-diarylthiazole derivatives as cb-1 ligands | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | disclosed |
| EP-1581214-A1 | 4,5-DIARYLTHIAZOLE DERIVATIVES AS CB-1 LIGANDS | Astrazeneca AB (SE) | 2005-10-05 | — | — | EP | disclosed |
| EP-1492779-A1 | THIAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC, AGONISTIC OR PARTIAL AGONISTIC ACTIVITY | Solvay Pharmaceuticals B.V. (NL) | 2005-01-05 | — | — | EP | disclosed |
| US-20040266841-A1 | Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity | ABBVIE B.V. (NL) | 2004-12-30 | — | — | US | disclosed |
| WO-2004058255-A1 | 4, 5-DIARYLTHIAZOLE DERIVATIVES AS CB-1 LIGANDS | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
| WO-2003078413-A1 | THIAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC, AGONISTIC OR PARTIAL AGONISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266841-A1 | Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity | CNR1, CNR2, CCKAR | CNR1 1/4885CNR2 2/4885EIF4E 3704/4885 |
| US-20060122229-A1 | 4,5-diarylthiazole derivatives as cb-1 ligands | CNR1, CNR2, NPY4R | CNR1 1/4885CNR2 2/4885EIF4E 3935/4885 |
| US-20060141043-A1 | Aqueous dispersion comprising stable nanoparticles of a water-insoluble thiazole derivative and excipients like middle chain triglycerides | CETP, LIPC, LIPA | CNR1 4668/4885CNR2 4688/4885EIF4E 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.